Back to Search Start Over

T Lymphocytes transduced with a lentiviral vector expressing F12-Vif are protected from HIV-1 infection in an APOBEC3G-independent manner.

Authors :
Vallanti G
Lupo R
Federico M
Mavilio F
Bovolenta C
Source :
Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2005 Oct; Vol. 12 (4), pp. 697-706.
Publication Year :
2005

Abstract

The viral infectivity factor (Vif) is an essential component of the HIV-1 infectious cycle. Vif counteracts the action of the cytidine deaminase APOBEC3G (AP3G), which confers nonimmune antiviral defense against HIV-1 to T lymphocytes. Disabling or interfering with the function of Vif could represent an alternative therapeutic approach to AIDS. We have expressed a natural mutant of Vif, F12-Vif, in a VSV-G-pseudotyped lentiviral vector under the Tat-inducible control of the HIV-1 LTR. Conditional expression of F12-Vif prevents replication and spreading of both CXCR4 and CCR5 strains of HIV-1 in human primary T lymphocyte and T cell lines. T cells transduced with F12-Vif release few HIV-1 virions and with reduced infectivity. Several lines of evidence indicate that HIV-1 interference requires the presence of both wild-type and F12-Vif proteins, suggesting a dominant-negative feature of the F12-Vif mutant. Surprisingly, however, the F12-Vif-mediated inhibition does not depend on the reestablishment of the AP3G function.

Details

Language :
English
ISSN :
1525-0016
Volume :
12
Issue :
4
Database :
MEDLINE
Journal :
Molecular therapy : the journal of the American Society of Gene Therapy
Publication Type :
Academic Journal
Accession number :
16039909
Full Text :
https://doi.org/10.1016/j.ymthe.2005.05.014